Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) is expected to release its earnings data on Tuesday, March 25th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.
Atossa Therapeutics Trading Down 1.7 %
Shares of NASDAQ:ATOS traded down $0.01 during trading on Monday, reaching $0.74. The stock had a trading volume of 305,248 shares, compared to its average volume of 1,016,818. The firm's 50-day simple moving average is $0.81 and its 200 day simple moving average is $1.12. Atossa Therapeutics has a one year low of $0.66 and a one year high of $2.31. The company has a market capitalization of $93.18 million, a P/E ratio of -3.37 and a beta of 1.20.
Institutional Investors Weigh In On Atossa Therapeutics
A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE increased its position in Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 51.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,475 shares of the company's stock after acquiring an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 12.74% of the company's stock.
Analyst Upgrades and Downgrades
ATOS has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research note on Wednesday, March 12th. Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a research note on Monday, December 9th.
Get Our Latest Research Report on ATOS
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Featured Articles
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
